The Top 5 Biosimilar Articles for the Week of November 4

Number 5: By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.

Number 4: An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.

Number 3: A recent study found that the rising prevalence of inflammatory bowel disease (IBD), approaching 1% in Europe and North America, is accompanied by increasing healthcare costs due to shifts in care and higher hospitalization expenses, presenting challenges to sustainability and prompting strategies for personalized, cost-effective care.

Number 2: Panelists emphasized the need for transparency and policy reforms in pharmacy benefit management (PBM) to improve accessibility, affordability, and fair competition for adalimumab biosimilars.

Number 1: An article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products could be reconsidered, suggesting they might be eligible for new drug applications (NDAs) or a hybrid biosimilar category due to their unique characteristics and increasing prevalence.

To read all of these articles and more, visit centerforbiosimilars.com.